Cantor Fitzgerald Forecasts Insmed FY2025 Earnings

Insmed Incorporated (NASDAQ:INSM) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Insmed in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings per share of ($4.65) for the year. The consensus estimate for Insmed’s current full-year earnings is ($5.44) per share.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the prior year, the company posted ($1.10) earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis.

Several other brokerages also recently weighed in on INSM. Bank of America increased their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Stock Up 5.8 %

Shares of NASDAQ INSM opened at $76.75 on Wednesday. Insmed has a 1 year low of $21.92 and a 1 year high of $80.53. The firm has a 50-day simple moving average of $71.19 and a two-hundred day simple moving average of $72.72. The company has a market cap of $13.73 billion, a P/E ratio of -13.83 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Institutional Trading of Insmed

A number of institutional investors have recently made changes to their positions in the business. Darwin Global Management Ltd. purchased a new stake in Insmed in the second quarter valued at about $237,076,000. Vestal Point Capital LP boosted its stake in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares in the last quarter. Clearbridge Investments LLC grew its position in Insmed by 76.8% during the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after purchasing an additional 714,539 shares during the last quarter. Farallon Capital Management LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $38,056,000. Finally, Fred Alger Management LLC purchased a new position in shares of Insmed in the second quarter worth about $33,404,000.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO William Lewis sold 31,805 shares of Insmed stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90. Following the completion of the transaction, the chief executive officer now directly owns 379,534 shares in the company, valued at $26,635,696.12. This represents a 7.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,740 shares of company stock worth $7,161,294 over the last 90 days. Company insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.